Worth reading
50Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Announced details
Stem cell gene therapy technology (Development Code: SR-GT1)
Applicable field (uses covered by this announcement)
Curative treatment of dystrophic epidermolysis bullosa
Relationship between the counterparty and the company
StemRIM Inc.4599
Relationship with the Company
当社と大阪大学は「再生誘導医薬®」開発研究を進めてきた。特許の出願人は大阪大学。資本関係・人的関係の記載はNot disclosed。
CounterpartyOsaka University National University Corporation
国立大学法人大阪大学。その他の所在地・代表者・事業内容・資本金・設立年はNot disclosed。
Registration number and expiry date
出願番号：特願2024-124327。登録番号：未定。出願地域：日本。有効期限はNot disclosed。
Impact on Business Performance
There will be no impact on full-year results for the fiscal year ending July 2026. Any material matter requiring disclosure will be disclosed promptly.
The company does not address Contract Value / Offering price.
Source (materials cited by the company)
国立研究開発法人日本医療研究開発機構（AMED）の支援。2024年12月6日付「AMED公募課題『令和6年度 再生・細胞医療・遺伝子治療産業化促進事業』採択のお知らせ」
| Item | Details |
|---|---|
| Names of Products / Services Covered | Stem cell gene therapy technology (Development Code: SR-GT1) |
| Counterparty | Osaka University National University Corporation |
| Counterparty overview | 国立大学法人大阪大学。その他の所在地・代表者・事業内容・資本金・設立年はNot disclosed。 |
| Relationship with the Company | 当社と大阪大学は「再生誘導医薬®」開発研究を進めてきた。特許の出願人は大阪大学。資本関係・人的関係の記載はNot disclosed。 |
| Applicable area | Curative treatment of dystrophic epidermolysis bullosa |
| Registration number and expiry date | 出願番号：特願2024-124327。登録番号：未定。出願地域：日本。有効期限はNot disclosed。 |
| Impact on Business Performance | There will be no impact on full-year results for the fiscal year ending July 2026. Any material matter requiring disclosure will be disclosed promptly. |
| Source | 国立研究開発法人日本医療研究開発機構（AMED）の支援。2024年12月6日付「AMED公募課題『令和6年度 再生・細胞医療・遺伝子治療産業化促進事業』採択のお知らせ」 |
Items this document does not state (10)
Contract ValueOffering priceContract DateLaunch dateAward/certification nameAwarding / certifying bodyLocationLocation scaleQuantitative EffectsUsage history
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.当社と大阪大学が進めてきた「再生誘導医薬®」開発研究を基盤に、体内再生誘導治療を遺伝性難病の根治的治療へ発展させるため。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.